Free tool
FAERS Monitor: Caduet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021540 or its brand name (Caduet, Amlodipine Besylate, Atorvastatin Calcium). Reports on generic versions are filed under their own applications.
Reports
4,091
Serious
2,658
65% of reports
Hospitalization
1,073
Death reported
358
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness184
- drug ineffective178
- nausea178
- fatigue175
- malaise163
- pain148
- dyspnoea146
- death144
- headache133
- hypertension133
- asthenia126
- diarrhoea124
- oedema peripheral119
- fall118
- pruritus106
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 52 |
| 2006 | 102 |
| 2007 | 193 |
| 2008 | 169 |
| 2009 | 217 |
| 2010 | 622 |
| 2011 | 291 |
| 2012 | 356 |
| 2013 | 275 |
| 2014 | 250 |
| 2015 | 226 |
| 2016 | 176 |
| 2017 | 161 |
| 2018 | 129 |
| 2019 | 177 |
| 2020 | 199 |
| 2021 | 105 |
| 2022 | 98 |
| 2023 | 89 |
| 2024 | 79 |
| 2025 | 64 |
| 2026 | 57 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| oedema peripheralSignal | 119 | 5.0 | 4.2 | 381 |
| hypertensionSignal | 133 | 3.2 | 2.7 | 204 |
| malaise | 163 | 1.9 | 1.6 | 71 |
| dizziness | 184 | 1.9 | 1.6 | 79 |
| fall | 118 | 1.8 | 1.5 | 44 |
| asthenia | 126 | 1.7 | 1.5 | 38 |
| pruritus | 106 | 1.4 | 1.2 | 13 |
| dyspnoea | 146 | 1.3 | 1.1 | 12 |
| pain | 148 | 1.2 | 1.1 | 7 |
| nausea | 178 | 1.2 | 1.0 | 4 |
| fatigue | 175 | 1.2 | 1.0 | 4 |
| headache | 133 | 1.1 | 0.9 | 1 |
| diarrhoea | 124 | 1.0 | 0.8 | 0 |
| death | 144 | 0.9 | 0.7 | 3 |
| drug ineffective | 178 | 0.7 | 0.6 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.